Pharmaceutical

Janssen’s Talvey adds European approval on top of its US authorisation

Janssen’s bispecific antibody received conditional approval as a subcutaneous therapy based on Phase I/II trial data.

Aug 22, 2023 - 20:00
Janssen’s Talvey adds European approval on top of its US authorisation
Janssen’s bispecific antibody received conditional approval as a subcutaneous therapy based on Phase I/II trial data.
Read the original article

Tags:

Previous Article

Halia plans two trials testing its anti-inflammatory lead candidate

Next Article

How a flexible FSP model fills the talent gap

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Boehringer to leverage IBM’s technologies for antibody discovery 

Boehringer to leverage IBM’s technologies for antibody ...

Nov 28, 2023

No nitrosamines: How parenteral packaging is evolving to meet today’s E&L challenges

No nitrosamines: How parenteral packaging is evolving t...

May 23, 2024

STAT+: In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years

STAT+: In major test for eGenesis, gene-edited pig kidn...

Oct 12, 2023